BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golden AR, Fear T, Baxter M, Adam HJ, Martin I, Demczuk W, Karlowsky JA, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA). Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011-2018. Diagn Microbiol Infect Dis 2021;101:115447. [PMID: 34192638 DOI: 10.1016/j.diagmicrobio.2021.115447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Silva PH, Vázquez Y, Campusano C, Retamal-díaz A, Lay MK, Muñoz CA, González PA, Kalergis AM, Bueno SM. Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection. Front Cell Infect Microbiol 2022;12:949469. [DOI: 10.3389/fcimb.2022.949469] [Reference Citation Analysis]
2 Ryman J, Weaver J, Yee KL, Sachs JR. Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children. Expert Rev Vaccines 2022;:1-7. [PMID: 35997125 DOI: 10.1080/14760584.2022.2112179] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Golden AR, Adam HJ, Baxter M, Martin I, Demczuk W, Mulvey MR, Karlowsky JA, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA). Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018. Vaccine 2021;39:5474-83. [PMID: 34454785 DOI: 10.1016/j.vaccine.2021.08.061] [Reference Citation Analysis]